Cosmo Pharmaceuticals N.V.

SWX:COPN Stock Report

Market Cap: CHF1.1b

Cosmo Pharmaceuticals Dividend

Dividend criteria checks 2/6

Cosmo Pharmaceuticals is a dividend paying company with a current yield of 2.73%.

Key information

2.7%

Dividend yield

2,808%

Payout ratio

Industry average yield2.4%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per shareCHF0.071
Dividend yield forecast in 3Y1.3%

Recent dividend updates

Recent updates

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Mar 28
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Mar 26
Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Dec 01
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 29
Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Nov 24
We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Mar 31
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Aug 02
These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well

Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

May 20
Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)

Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

Apr 03
Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly

When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Mar 07
When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?

What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Feb 01
What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?

Cosmo Pharmaceuticals'(VTX:COPN) Share Price Is Down 47% Over The Past Five Years.

Dec 27
Cosmo Pharmaceuticals'(VTX:COPN) Share Price Is Down 47% Over The Past Five Years.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: COPN's dividend payments have been volatile in the past 10 years.

Growing Dividend: COPN's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

Cosmo Pharmaceuticals Dividend Yield vs Market
How does COPN dividend yield compare to the market?
SegmentDividend Yield
Company (COPN)2.7%
Market Bottom 25% (CH)2.1%
Market Top 25% (CH)4.2%
Industry Average (Pharmaceuticals)2.4%
Analyst forecast in 3 Years (COPN)1.3%

Notable Dividend: COPN's dividend (2.73%) is higher than the bottom 25% of dividend payers in the Swiss market (2.06%).

High Dividend: COPN's dividend (2.73%) is low compared to the top 25% of dividend payers in the Swiss market (4.2%).


Earnings Payout to Shareholders

Earnings Coverage: With its high payout ratio (2808.2%), COPN's dividend payments are not well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (175.3%), COPN's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.